Prostate cancer Cancer
Conditions
Interventions
Patients will undergo up to three MRI scans lasting approximately 1 hour each, including placement of up to two separate endorectal coils. The study will necessitate one intravenous cannula for venous
Sponsors
Cambridge University Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
Male
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Men aged >18 years 2. For surgery or hormone therapy patients, biopsy-proven intermediate-risk or high-risk prostate cancer (Appendix 1), with a clinical treatment plan 3. Previous diagnostic clinical MRI demonstrates a visible tumour
Exclusion criteria
Exclusion criteria: 1. Previous treatment for prostate cancer 2. Clinical contraindication to MRI 3. Renal impairment as defined by a glomerular filtration rate (GFR) <30 ml/min
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured by MRI before and after treatment: 1. 13C. Spatial maps of area under the curve (AUC) timecourse sums of signals from hyperpolarized pyruvate, lactate, and any other metabolites detected, and ratios between these metabolite AUCs. Also estimates of the kinetic rate constants of conversion between injected tracer pyruvate and the metabolites formed (lactate, other). The timecourse typically covers approximately 1 minute beginning approximately 16 seconds after the start of injection. 2. Sodium. Maps of estimated millimolar sodium content over the 3D volume of tissue investigated. Optionally also maps of the ratio of intracellular-weighted signal to total sodium signal. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Levels of metabolites such as pyruvate, lactate in venous blood as measured by liquid chromatography mass spectrometry (LCMS) before and after treatment 2. Total activities of lactate dehydrogenase (LDH) in venous blood as measured by LDH assay before and after treatment 3. Levels of carbonic anhydrase IX, CD31, Hypoxia-Inducible Factor-1a (HIF-1a), Ki67, monocarboxylic acid (MCT1/4) transporters, LDH expression and lactate/pyruvate measured in prostatectomy or biopsy specimens by immunohistochemistry before and after treatment. Immunohistochemistry results will be converted into semi-quantitative data using an appropriate density measurement of staining. | — |
Countries
England, United Kingdom
Contacts
Public ContactMarta Wylot
Outcome results
None listed